Suboptimal Use of SGLT2 Inhibitors in Individuals With Diabetes and Heart Failure
A team of investigators assessed the frequency with which patients with type 2 diabetes and heart failure were prescribed sodium-glucose co-transporter 2 inhibitors.
A team of investigators assessed the frequency with which patients with type 2 diabetes and heart failure were prescribed sodium-glucose co-transporter 2 inhibitors.
A team of investigators sought to identify the impact of hyperglycemia on the severity of and outcomes associated with stroke in patients with type 2 diabetes.
Study authors identified whether the hemoglobin A1c threshold level where reduction in bone turnover begins.
Researchers sought to determine whether ertugliflozin plus insulin would help redice body weight, systolic blood pressure, HbA1c, and other metrics among individuals with T2DM.
Researchers investigated the effects of RAAS antagonism on the severity of COVID-19 in patients with obesity-related hypertension.
A larger percentage of weight loss regained after an intensive lifestyle intervention was positively associated with certain cardiometabolic risk factors in type 2 diabetes.